Tilray | TRLY - Operating Profit


Tilray reported $-20.01M in Operating Profit for its fiscal quarter ending in September of 2025.





Operating Profit Change Date
Acasti Pharma USD -2.53M 560K Sep/2025
Akebia Therapeutics USD -5.45M 9.4M Dec/2025
Alaunos Therapeutics USD -1.01M 175K Mar/2026
Aurora Cannabis CAD -10.03M 25.76M Mar/2026
Avita Medical AUD -10.41M 742K Dec/2025
Canopy Growth CAD -27.47M 14.81M Mar/2026
Cronos Group USD 7.6M 9.06M Jun/2026
Dianthus Therapeutics USD -46.53M 23.01M Mar/2026
Divis Laboratories Ltd INR 11.29B 3.15B Jun/2026
Ionis Pharmaceuticals USD -102.29M 15.71M Jun/2026
IQVIA Holdings USD 2.6B 2.03B Jun/2026
Knight Therapeutics CAD 6.21M 3.27M Dec/2025
Moderna USD -815M 573M Jun/2026
Organigram Holdings CAD -9.79M 10.33M Mar/2026
Organon & Co USD 266M 49M Mar/2026
Revvity USD 126.14M 43.36M Jun/2026
Tectonic Therapeutic USD -27.3M 5.78M Mar/2026
Tilray USD -20.01M 9.34M Sep/2025
Viatris USD 73.7M 93.9M Jun/2026
Xeris Pharmaceuticals USD 7.92M 8.86M Mar/2026
Zealand Pharma A/S -539M 168.05M Mar/2026